Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Posted by Stanley Muller on Nov 6th, 2026

Sana Biotechnology (NASDAQ:SANA – Get Free Report) announced its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Stock Performance

Shares of SANA traded up $0.03 during trading hours on Friday, hitting $2.37. The stock had a trading volume of 2,288,443 shares, compared to its average volume of 2,997,985. Sana Biotechnology has a 1-year low of $2.22 and a 1-year high of $5.49. The firm has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $3.36.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SANA. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Bank of America lowered their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

Check Out Our Latest Report on SANA

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.